JORGE FERNANDEZ retweeted
❤️🩹 Does heart failure change the benefits of tirzepatide? SURPASS-CVOT shows fewer HF events and MACE-4 vs dulaglutide in patients with T2D and HF. Promising findings! 💉📉
👉doi.org/10.1093/eurjpc/zwag4…
JORGE FERNANDEZ retweeted
How Ozempic Works
- Ozempic works by mimicking a natural gut hormone, helping regulate appetite, blood sugar, and digestion. Its active ingredient, semaglutide, acts on the brain, pancreas, liver, and stomach to help manage type 2 diabetes and support weight loss.
JORGE FERNANDEZ retweeted
Replying to @JAMA_current @ObesitySociety
💬 Editor's Note by JAMA Associate Editor Deborah Wexler, MD, MSc, and JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS: With 1.1 billion people worldwide affected by #Obesity, newer glucagon-like peptide-1 and multiple receptor agonist therapies have changed the field, but access, adverse effects, and integration into broader strategies addressing biological, behavioral, socioeconomic, and environmental factors remain limited.
This call for papers on the future of obesity seeks timely and novel research articles and opinion manuscripts on topics ranging from novel therapeutics to prevention and sustainable, comprehensive care.
🔗 Learn more: ja.ma/4zvfVdA
JORGE FERNANDEZ retweeted
Replying to @JAMA_current @ObesitySociety
Join JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and leading experts in #obesity research, treatment, and policy for an inside look at Toward a Healthier Future: The #JAMASummit Report on Obesity.
Featuring report authors Derek Angus, MD, MPH, Lotte Bjerre Knudsen, DMSc, Robert Kushner, MD, MS, and Marion Nestle, PhD, MPH, this discussion will examine the most important insights, debates, and priorities emerging from the Summit and explore what it will take to achieve meaningful progress in obesity prevention and treatment over the next 1-2 years. The webinar will also include a live Q&A session with the panelists.
➡️ Register now: ja.ma/4kXaG2p
JORGE FERNANDEZ retweeted
Replying to @JAMA_current @ObesitySociety
Today, JAMA published Toward a Healthier Future Through Obesity Prevention and Care: The #JAMASummit Report on Obesity.
The report highlights the significant opportunity presented by the emergence of effective #obesity management medications to help curb the prevalence of obesity while emphasizing that no single intervention will be sufficient to address this complex disease.
🔗 Read the full report: ja.ma/3WJvVuJ
#ObesityWeek #OW2026 @ObesitySociety
JORGE FERNANDEZ retweeted
Replying to @JAMA_current @ObesitySociety
💬 Editorial by William Heerman, MD, MPH, Lilianna Suarez, MD, MPH, and Sarah Armstrong, MD: #PediatricObesity pharmacotherapy has shifted from limited treatment options to multiple effective choices, with tirzepatide adding substantial BMI reduction to behavioral treatment in adolescents with obesity.
Clinical care now requires individualized medication selection, dose escalation, and monitoring rather than routine escalation to the maximum tolerated dose.
ja.ma/4zK6jwf
#ObesityWeek #OW2026 @ObesitySociety
JORGE FERNANDEZ retweeted
Replying to @JAMA_current @ObesitySociety
Among adolescents with #Obesity or overweight with obesity-related complications, once-weekly tirzepatide plus healthy lifestyle intervention led to greater reductions in #BMI vs placebo over 72 weeks.
Tirzepatide was also associated with improvements in body weight, waist circumference, and physical functioning, supporting its potential clinical relevance for adolescent obesity treatment.
ja.ma/4zQkTT7
#ObesityWeek #OW2026 @ObesitySociety









